Research has considerably improved our understanding of hematologic diseases and resulted in many innovative, groundbreaking discoveries in disease mechanisms and therapies. Many of these findings resulted in better treatments with durable effects and lower toxicity.

To promote exchange of information on new findings and much more, EHA established its open access journal HemaSphere. Recently a special edition on CAR T therapy has been published with the following articles, and new articles will be added:

Special edition CAR T Cells of HemaSphere.

Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia, Delgado, Julio; Caballero-Baños, Miguel; Ortiz-Maldonado, Valentín; Castellà, Maria; Magnano, Laura; Juan, Manel; Urbano-Ispizua, Álvaro, HemaSphere. 3(2):e174, April 2019.

In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy, Garcia Borrega, Jorge; Gödel, Philipp; Rüger, Maria Adele; Onur, Özgür A.; Shimabukuro-Vornhagen, Alexander; Kochanek, Matthias; Böll, Boris, HemaSphere. 3(2):e191, April 2019.

CAR T Cell Toxicity: Current Management and Future Directions, Yáñez, Lucrecia; Sánchez-Escamilla, Miriam; Perales, Miguel-Angel HemaSphere. 3(2):e186, April 2019.

CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope, Hopfinger, Georg; Jäger, Ulrich; Worel, Nina, HemaSphere. 3(2):e185, April 2019.

CAR-T Cells: Future Perspectives, Charrot, Sarah; Hallam, Simon, HemaSphere. 3(2):e188, April 2019

CAR T Cells: A Snapshot on the Growing Options to Design a CAR, Holzinger, Astrid; Abken, Hinrich, HemaSphere. 3(1):e172, February 2019.

Chimeric Antigen Receptor-T Cell Therapy: Practical Considerations for Implementation in Europe, Buechner, Jochen; Kersten, Marie José; Fuchs, Miriam; Salmon, Florence; Jäger, Ulrich, HemaSphere. 2(1):e18, January-February 2018.



Research Grants

As part of its Research Grants Program, EHA is going to launch a grant dedicated on immunotherapy in September 2019. Stay tuned for the opening of the call!